Nestle Bets $2.6 Billion on Aimmune’s Peanut Allergy Treatment

(Bloomberg) -- Nestle SA agreed to buy Aimmune Therapeutics Inc. for $2.6 billion, adding a promising peanut allergy treatment to its portfolio of coffee, snacks and water.
BQ Install

Bloomberg Quint

Add BloombergQuint App to Home screen.